PRODUCTS SOLD ON PEPTIDESLABUSA.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
PRODUCTS SOLD ON PEPTIDESLABUSA.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
$294.00
Cagrilintide + Semaglutide USA – Buy Online | In Stock & Ready to Ship
Buy Cagrilintide + Semaglutide in the USA with fast domestic shipping and guaranteed ≥99% purity — fully verified with COA and HPLC documentation. A trusted choice for USA research teams studying appetite regulation and metabolic pathways, this compound combination is available in multiple formats to suit varying project needs. No international delays — just reliable, domestically sourced peptides USA researchers can count on.
For research use only. Not intended for human or veterinary use.
Cagrilintide and Semaglutide — together known as CagriSema — is a dual-peptide research combination studied for its complementary effects on appetite regulation, metabolic function, and weight-related pathways, and one of the most closely followed research combinations in obesity and metabolic science in the USA today.
Researchers, labs, and institutions across the United States can source verified, research-grade Cagrilintide and Semaglutide individually or as a combined research set, with fast dispatch, full documentation, and third-party verified purity.
✅ ≥99% Purity — HPLC & Mass Spectrometry Verified
✅ Batch-Specific Certificate of Analysis (CoA) Included
✅ Third-Party Tested | GMP Manufactured
✅ Fast Dispatch to USA — Tracked Shipping Available
Cagrilintide is a long-acting synthetic analogue of amylin — a hormone naturally co-secreted with insulin by the pancreas in response to food intake. Amylin plays a key role in signaling satiety to the brain, slowing gastric emptying, and suppressing post-meal glucagon release. Cagrilintide is engineered to have a significantly extended half-life compared to native amylin, making it a practical research tool for studying amylin receptor pathways over time.
As a dual agonist of amylin and calcitonin receptors, cagrilintide acts on brain regions involved in both homeostatic and hedonic appetite control — including the hypothalamus and hindbrain — making it distinct in its mechanism from GLP-1-based compounds.
Semaglutide is a GLP-1 receptor agonist (glucagon-like peptide-1) — a class of compounds that mimic the action of the naturally occurring incretin hormone GLP-1. In research settings, semaglutide is studied for its effects on insulin secretion, glucagon suppression, gastric emptying, and appetite signaling through GLP-1 receptors in the brain and gut.
Semaglutide is one of the most extensively studied GLP-1 analogues in metabolic research globally and forms a key reference compound in obesity, type 2 diabetes, and cardiovascular metabolic research programs across the USA.
CagriSema is the research designation for the co-administration of Cagrilintide and Semaglutide — combining a GLP-1 receptor agonist with a long-acting amylin analogue to target two complementary appetite and metabolic pathways simultaneously. The rationale behind combining the two compounds is that GLP-1 and amylin pathways act through distinct but synergistic mechanisms in the brain’s appetite-regulating centers, with the combination producing metabolic effects that exceed either compound studied alone.
CagriSema has been the subject of large-scale Phase 3 clinical trials (the REDEFINE program) and was submitted to the FDA for approval by Novo Nordisk in December 2025 — making it one of the most actively tracked compounds in the USA peptide and metabolic research space today.
In research settings, the CagriSema combination has been studied for its effects on:
Both compounds are research tools only and are not approved for self-administration or therapeutic use.
Published research on CagriSema spans Phase 2 and Phase 3 clinical trials, with findings published in the New England Journal of Medicine in 2025 — among the highest-profile metabolic research publications in recent years.
REDEFINE 1 — Phase 3 Trial (Non-Diabetic Obesity)
The REDEFINE 1 trial enrolled 3,417 adults with obesity or overweight alongside at least one obesity-related complication. Participants receiving the CagriSema combination achieved an average body weight reduction of 20.4% over 68 weeks, compared to 3.0% with placebo. More than half of participants in the CagriSema group achieved a weight reduction of 20% or more, and approximately one in four reached 30% or greater weight reduction. Improvements in systolic blood pressure, waist circumference, and lipid levels were also observed.
REDEFINE 2 — Phase 3 Trial (Type 2 Diabetes)
REDEFINE 2 enrolled 1,206 adults with type 2 diabetes and overweight or obesity. The CagriSema group achieved a mean body weight reduction of 13.7% over 68 weeks versus 3.4% in the placebo group. Glycemic improvements were substantial — 73.5% of the CagriSema group reached an HbA1c of 6.5% or below compared to 15.9% in the placebo group, highlighting the combination’s dual-pathway effect on both weight and glucose regulation.
Phase 2 Data and Head-to-Head Comparisons
Earlier Phase 2 data across 17 USA research sites showed average weight loss of 15.6% at 32 weeks with CagriSema — comparable to tirzepatide data from similar timepoints. The combination consistently outperformed semaglutide alone and cagrilintide alone, supporting the complementary mechanism hypothesis.
Mechanism Research — Dual Pathway Synergy
Researchers have proposed that the superior outcomes observed with CagriSema result from the complementary action of both molecules on appetite regulation through direct effects in the hypothalamus, hindbrain, and septum — brain areas governing both hedonic (reward-driven) and homeostatic (energy-balance) eating behavior.
All Phase 3 trial data referenced above is from clinical research conducted under institutional oversight. Cagrilintide and Semaglutide are supplied here as research compounds only and are not approved for human therapeutic use.
When you buy Cagrilintide or Semaglutide research peptides in the USA through our platform, every order includes:
We supply USA research peptides to licensed researchers, universities, and institutions — with cold-chain compliant packaging designed to maintain peptide integrity throughout transit.
| Parameter | Specification |
|---|---|
| Purity | ≥99% (HPLC & MS Verified) |
| Form | White Lyophilized Powder |
| Classification | Long-acting amylin/calcitonin receptor agonist |
| Solubility | Sterile water / 0.1% acetic acid |
| Storage (powder) | -20°C, stable 24+ months |
| Storage (reconstituted) | 2–8°C, use within 2–4 weeks |
| Parameter | Specification |
|---|---|
| Purity | ≥99% (HPLC & MS Verified) |
| Form | White Lyophilized Powder |
| Classification | GLP-1 receptor agonist |
| Molecular Weight | 4,113.58 g/mol |
| Solubility | Sterile water / PBS |
| Storage (powder) | -20°C, stable 24+ months |
| Storage (reconstituted) | 2–8°C, use within 2–4 weeks |
| Feature | CagriSema | Semaglutide Alone | Tirzepatide |
|---|---|---|---|
| Mechanism | GLP-1 + Amylin/Calcitonin | GLP-1 only | GLP-1 + GIP |
| Appetite Pathways Targeted | 2 (distinct) | 1 | 2 (overlapping) |
| Phase 3 Weight Loss Data | ~20.4% (68 weeks) | ~14.9% (68 weeks) | ~20–22% (72 weeks) |
| Type 2 Diabetes Research | Yes (REDEFINE 2) | Yes | Yes |
| FDA Submission | Filed Dec 2025 | Approved | Approved |
Can I buy Cagrilintide and Semaglutide research peptides in the USA?
Yes. We supply research-grade Cagrilintide and Semaglutide with fast tracked dispatch across the United States. All orders include full purity documentation and integrity-maintained packaging for research use.
What is CagriSema?
CagriSema is the research and development name for the combination of Cagrilintide (2.4 mg) and Semaglutide (2.4 mg), studied as a dual-mechanism approach to obesity and metabolic research. It combines a GLP-1 receptor agonist with a long-acting amylin analogue to target complementary appetite and metabolic pathways.
How is Cagrilintide different from Semaglutide?
Semaglutide works via GLP-1 receptors, primarily in the gut and brain. Cagrilintide works via amylin and calcitonin receptors — a distinct set of pathways. Because they act through different mechanisms, research suggests the combination produces synergistic effects that neither compound achieves alone.
Is CagriSema FDA approved?
As of early 2026, CagriSema is not yet FDA approved. Novo Nordisk submitted a New Drug Application to the FDA in December 2025. It remains an investigational compound and is supplied here for research purposes only.
What purity level should research-grade Semaglutide and Cagrilintide be?
≥98% is the accepted minimum for research-grade peptides, though ≥99% is preferred for receptor binding and metabolic assay work. All of our USA peptides — including Semaglutide and Cagrilintide — are HPLC and mass spectrometry verified to ≥99%.
How quickly are research peptides delivered in the USA?
Orders are dispatched promptly with tracked shipping. Most USA orders arrive within 3–5 business days.
Where can I find Semaglutide and Cagrilintide for sale in the USA?
We offer both Semaglutide and Cagrilintide for sale in the USA exclusively for licensed research use, with full documentation and verified purity included as standard with every order.
Research Disclaimer: Cagrilintide and Semaglutide are supplied exclusively for legitimate scientific research purposes in licensed laboratory environments. These products are not intended for human consumption, self-administration, or therapeutic use of any kind. They must be handled by qualified researchers in accordance with all applicable US federal and state regulations and institutional ethics guidelines. By purchasing, you confirm that these compounds will be used solely for approved in-vitro or pre-clinical research.
Receive News
